Xolair: breathing easy over FDA approval

Xolair, developed by Genentech, Novartis and Tanox, reduces the number of attacks in severe allergic asthmatics. However prescribing restrictions, safety concerns and high cost are expected to limit sales to $593 million by 2010. The drug's best chance of success is through label extensions for pediatric use and for allergic rhinitis.<BR />

Published By Datamonitor

Yahoo!/HSBC: PayDirect from New York to Hong Kong

Published By Datamonitor

Yahoo!: fighting recession with business services

Published By Datamonitor

Yahoo!: porn doesn't pay

Published By Datamonitor

Yet another worry for Indian offshoring companies

It was recently reported that various problems with the Indian outsourcing industry are forcing UK and European firms to look elsewhere for their offshore provision. The issues cited include big wage rises, skills shortages, and incidents around data security. Such problems threaten to topple India's leading offshoring position, and come as rivals are growing ever stronger.

Published By Datamonitor

Yodlee: stepping beyond basic aggregation

Published By Datamonitor

Young drivers: design matters

A raft of recent vehicle launches, in particular from Japanese manufacturers, has demonstrated the automotive industry's obsession with the so-called Generation-Y market. But designing specific lifestyle oriented vehicles is a gamble that may not pay off.

Published By Datamonitor

Zimmer: big advances through tiny holes

Zimmer has released positive preliminary results for its two-incision minimally invasive hip arthroplasty system, and also plans to open a training facility teaching surgeons how to implant these systems. But while the system can radically reduce recovery time, it involves an extremely difficult technique that most orthopaedic surgeons are unlikely to adopt.

Published By Datamonitor

Zimmer: spinal expansion would maximize Collagraft potential

The recent approval for these indications allows Zimmer to compete in the largest segment of the $200 million US market for bone growth substitutes. However, unless the company fully enters the spinal implant market - including the establishment of a spinal salesforce - Collagraft will not reach its sales potential.

Published By Datamonitor

ZymeTx: flu management program could be catching

Published By Datamonitor